Gene Therapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Findings from University of Manitoba advance knowledge in Alzheimer disease
May 15th, 2008
According to a study from Winnipeg, Canada, "Alzheimer's disease (AD) is a neurodegenerative disorder, due to excess amyloid-beta peptide (A beta). TGF-beta 1 and beta-catenin signaling pathways have been separately implicated in modulating A beta-neurotoxicity." "However, the underlying mechanisms remain unclear. Here, we report that TGF-beta 1 and nuclear Smad7 and beta-catenin levels were markedly upregulated in cortical brain regions of the TgCRND8 mice, a mouse model of familial Alzheimer's disease. Coimmunoprecipitation of cortical brain tissue lysates revealed an interaction between Smad7 and beta-catenin. This interaction which was significantly enhanced in the...
Source: Gene Therapy Weekly (2008-05-15)
|
